Bone morphogenic protein 6: A member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

Oncogene

Volumn 28, Issue 44, 2009, Pages 3866-3879

  Seckinger, A ^a   Meiner, T ^a   Moreaux, J ^b,c,d   Goldschmidt, H ^a,e   Fuhler, G M ^f   Benner, A ^g   Hundemer, M ^a   Reme T ^b,c,d   Shaughnessy, J D ^h   Barlogie, B ^h   Bertsch, U ^a   Hillengass, J ^a   Ho, A D ^a   Pantesco, V ^b,c,d   Jauch, A ^a   De Vos, J ^b,c,d   Rossi, J F ^b,c,d   Mohler T ^a,e   Klein, B ^b,c,d   Hose, D ^a,e  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HÔPITAL SAINT ELOI   (France)

^c INSERM   (France)

^d UNIV MONTPELLIER   (France)

^e Nationales Centrum fur Tumorerkrankungen   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Angiogenesis; Gene expression profiling; Multiple myeloma; Proliferation; Survival

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN CELL; MYELOMA CELL; OSSIFICATION; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BONE MORPHOGENETIC PROTEIN 6; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 70449097998     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.257     Document Type: Article

References (46)

1. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van RF, Zangari M et al. (2006). Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633-2638.
2. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102: 1115-1123.
3. Caplan AI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341-347.
4. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L et al. (2003). Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A: 1544-1552.
5. Clement JH, Sanger J, Hoffken K. (1999). Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80: 250-256.
6. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. (2007). Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088.
7. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C et al. (2005). Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44: 194-203.
8. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65: 8274-8285.
9. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC et al. (2001). Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98: 771-780.
10. De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K et al. (2006). Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 210: 86-104.
11. Du J, Yang S, Wang Z, Zhai C, Yuan W, Lei R et al. (2007). Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways. J Cell Biochem 103: 1584-1597.
12. Durie BG. (1986). Staging and kinetics of multiple myeloma. Semin Oncol 13: 300-309.
13. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M et al. (1999). Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112: 3519-3527.
14. Goldschmidt H, Sonneveld P, Cremer FW, van der HB, Westveer P, Breitkreutz I et al. (2003). Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82: 654-659.
15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. (2005). International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420.
16. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. (1997). Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57: 4427-4431. (Pubitemid 27413455)
17. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. (2004). Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64: 8276-8284.
18. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S et al. (2006). Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107: 4484-4490.
19. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A et al. (2009a). Induction of angiogenesis by normal and malignant plasma cells. Blood 114: 128-143.
20. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J et al. (2009b). Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113: 4331-4340.
21. Irie A, Habuchi H, Kimata K, Sanai Y. (2003). Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 308: 858-865.
22. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF et al. (1998). The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100: 637-646.
23. Kawabata M, Imamura T, Miyazono K. (1998). Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9: 49-61. (Pubitemid 28280536)
24. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB et al. (2006). BMP-6 inhibits human bone marrow B lymphopoiesis-upregulation of Id1 and Id3. Exp Hematol 34: 72-81.
25. Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH. (2005). BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol 6: 9.
26. Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS et al. (2003). Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9: 6046-6051.
27. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E et al. (2003). Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78: 106-113.
28. Kochanowska I, Chaberek S, Wojtowicz A, Marczynski B, Wlodarski K, Dytko M et al. (2007). Expression of genes for bone morphogenetic proteins BMP-2, BMP-4 and BMP-6 in various parts of the human skeleton. BMC Musculoskelet Disord 8: 128.
29. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A et al. (2003). Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113-24117.
30. Kyle RA, Rajkumar SV. (2004). Multiple myeloma. N Engl J Med 351: 1860-1873.
31. Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J et al. (2006). Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25: 7180-7191.
32. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E et al. (2007). Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109: 4914-4923.
33. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J et al. (2005). Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24: 3512-3524.
34. Massague J. (2000). How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
35. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. (2005). The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106: 1021-1030.
36. Nohe A, Keating E, Knaus P, Petersen NO. (2004). Signal transduction of bone morphogenetic protein receptors. Cell Signal 16: 291-299.
37. Ren R, Charles PC, Zhang C, Wu Y, Wang H, Patterson C. (2007). Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109: 2847-2853.
38. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O et al. (2004). Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23: 3024-3032.
39. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al. (2002). Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100: 1113-1122.
40. Trojan A, Tinguely M, Vallet S, Seifert B, Jenni B, Zippelius A et al. (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly 136: 400-403.
41. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87: 503-508.
42. Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F et al. (2002). Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106: 2263-2270.
43. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. (1999). Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 104: 131-137.
44. Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C et al. (2006). Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77: 75-83.
45. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. (2002). Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757.
46. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663.